Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: Semiquantitative and quantitative analysis

Annals of the Rheumatic Diseases

Volumn 61, Issue 12, 2002, Pages 1047-1054

  Crotti, T N ^a   Smith, M D ^b   Weedon, H ^b   Ahern, M J ^c   Findlay, D M ^a   Kraan, M ^d   Tak, P P ^d   Haynes, David R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE; AZATHIOPRINE; CD3 ANTIGEN; CD45 ANTIGEN; HYDROXYCHLOROQUINE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BIOPSY; CELL LINEAGE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EROSION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOLOGY; JOINT; MACROPHAGE; MALE; MEMORY CELL; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD3; ARTHRITIS, RHEUMATOID; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MACROPHAGES; MALE; MIDDLE AGED; OSTEOARTHRITIS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; SYNOVIAL FLUID;

EID: 0036892685     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.12.1047     Document Type: Article

References (49)

1. Van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: Results of a follow up study. J Rheumatol 1993;20:1288-96.
2. Woolley DE, Crossley MJ, Evanson JM. Collagenase at sites of cartilage erosion in the rheumatoid joint. Arthritis Rheum 1977;20:1231-9.
3. Trabandt A, Gay RE, Fassbender HG, Gay S. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum 1991;34:1444-51.
4. Tetlow LC, Woolley DE. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: Dual immunolocalisation studies. Ann Rheum Dis 1995;54:896-903.
5. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
6. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
7. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JMW, Ryan PFJ, et al. Expression of osteoclast differentiation factor at sites of bone resorption in collagen-induced arthritis. Arthritis Rheum 2000;43:821-6.
8. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001;40:623-30.
9. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31:653-61.
10. Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Rheumatology (Oxford) 1992;31:801-9.
11. Chu CQ, Field M, Feldman M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
12. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95.
13. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-85.
14. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-75.
15. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclast inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
16. Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
17. Quinn JMW, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res 2000;15:1459-66.
18. Horwood NJ, Kartsogiannis V, Quinn JMW, Romas Q, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-50.
19. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes. Arthritis Rheum 2001;44:1003-12.
20. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
21. Burgess TL, Qoan Y-X, Kaufman S, Ring BD, Van G, Capparelli C, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
22. Wong BR, Josien R, Lee SY, Sauter B, Li H-L, Steinman RM, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-80.
23. Anderson DM, Marakovsky E, Billinglsey WL. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic function. Nature 1997;390:175-9.
24. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun n-terminal kinase in T cells. J Biol Chem 1997;272:25190-4.
25. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Luthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
26. Yasuda H, Shima N, Nakagawa N, Mochizuki S-I, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
27. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
28. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-15.
29. Haynes DR, Barg E, Crotti TN, Weedon H, Atkins GJ, Zannatino A, et al. Osteoprotegerin (OPG) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies, osteoarthritis and normal controls. Rheumatology (Oxford) (in press).
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
31. Dougados M, van der Linden S, Juhlin H, Huiffeldt B, Amor B, Calin A. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218-27.
32. Gladman DD, Farewell VT. Progression in psoriatic arthritis: Role of time varying clinical indicators. J Rheumatol 1999;26:2409-13.
33. Altman R, Bloch DA, Bole G, Borenstain D, Brandt K. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
34. Smith MD, Chandran G, Youssef PP, Darby T, Ahern MJ. Day case knee arthroscopy under regional anaesthesia performed by rheumatologists. Aust NZ J Med 1996;26:108-9.
35. Smith MD, O'Donnell J, Highton J, Palmer DG, Rozenbilds M, Roberts-Thomson PJ. Immunohistochemical analysis of synovial membranes from inflammatory and non-inflammatory arthritides: Scarcity of CD5 positive B cells and IL2 receptor bearing T cells. Pathology 1992;24:19-26.
36. Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 2000;39:43-9.
37. Tak PP, Van Der Lubbe PA, Cauli A, Daha MR, Smeets TJM, Kluin PM, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
38. Parker A, Smith MD. Immunohistochemical detection of cytokines and cell adhesion molecules in the synovial membrane. Methods Find Exp Clin Pharmacol 1999;21:311.
39. Wikaningrum R, Highton J, Parker A, Coleman M, Hessian PA, Roberts-Thomson PJ, et al. Pathogenic mechanisms in the rheumatoid nodule: Comparison of pro-inflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. Arthritis Rheum 1998;41:1783-97.
40. Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovia membrane in rheumatoid arthritis. Arthritis Rheum 1997;40:1400-8.
41. Youssef PP, Parker A, Coleman M, Roberts-Thomson PJ, Ahern MJ, Smith MD. Variability in cytokine and cell adhesion molecule staining in arthroscopic synovial biopsies: Quantification using colour video image analysis. J Rheumatol 1997;24:2291-8.
42. Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
43. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
44. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 2001;83:902-11.
45. Fujikawa Y, Sabokbar A, Neale SD, Athanasou NA. Human osteoclast formation and bone resorption by monoytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996;55:816-22.
46. Itonaga Y, Fujikawa Y, Sabokbar A, Murray DW, Athanasou NA. Rheumatoid arthritis synovial macrophage osteoclast differentiation is osteoprotegerin ligand-dependent. J Patrol 2000 192:97-104.
47. Sakkas LI, Scanzello C, Johanson N, Burkholder J, Mitra A, Salgame P, et al. T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis. Clin Diagn Lab Immunol 1998;5:430-7.
48. Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology (Oxford) 2001;40:367-74.
49. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, et al. Connection between B lymphocyte and osteaclast differentiation pathways. J Immunol 2001;167:2625-31.